Are Australian clinicians monitoring medication adherence in hematological cancer survivors? Two cross-sectional studies

Experimental Hematology & Oncology - Tập 4 Số 1 - 2015
Marita Lynagh1, Tara Clinton‐McHarg2, Alix Hall1, Rob Sanson‐Fisher1, William Stevenson3, Campbell Tiley1, Alessandra Bisquera4
1School of Medicine and Public Health, Faculty of Health and Medicine, University of Newcastle, Level 4, West, HMRI Building, Callaghan, NSW, 2308, Australia
2School of Medicine and Public Health, Faculty of Health and Medicine, The University of Newcastle, 1127 Booth Building, Wallsend Campus, NSW, 2308, Australia
3Department of Haematology Royal North Shore Hospital Pathology North, The University of Sydney, Sydney, NSW, 2006, Australia
4The Clinical Research Design Information Technology and Statistical Support Unit (CReDITSS), The University of Newcastle, HMRI Building, Callaghan, Sydney, NSW, 2308, Australia

Tóm tắt

Từ khóa


Tài liệu tham khảo

Balkrishnan R. The importance of medication adherence in improving chronic-disease related outcomes. What we know and what we need to further know. Med Care. 2005;43(6):517–20.

Hohneker J, Shah-Mehta S, Brandt PS. Perspectives on adherence and persistence with oral mediations for cancer treatment. J Oncol Pract. 2011;7(1):65–7.

Darkow T, Henk HJ, Thomas SK, Feng W, Baladi JF, Goldberg GA, et al. Treatment interruptions and non-adherence with Imatinib and associated healthcare costs. Pharmacoeconomics. 2007;25(6):481–96.

Noens L, van Lierde MA, De Bock R, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: The ADAGIO study. Blood. 2009;113:5401–11.

Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28(10):2381–8.

Ibrahim AR, Eliasson L, Apperley JF, et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood. 2011;117(4):3733–6.

Richardson JL, Shelton DR, Krailo M, Levine AM. The effect of compliance with treatment on survival among patients with hematologic malignancies. J Clin Oncol. 1990;8(2):356–64.

National Institute for Clinical Excellence (NICE). Guidance on cancer services improving outcomes in haematological cancers: the manual. London: National Health Service; 2003.

Department of Health WA (DOHWA). Haematological Malignancy Model of Care. Perth, WA: Cancer and Palliative Care Network, Department of Health WA; 2009.

Osterberg L, Blaschke T. Adherence to Medication. N Engl J Med. 2005;353:487–97.

Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin. 2009;59:56–66.

Elwyn G, Edwards A, Britten N. ‘Doing prescribing’: how doctors can be more effective. Br Med J. 2003;327:864–7.

Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database of Systematic Reviews 2008(Issue 2):Art. No.:CD000011.

Iihara N, Tsukamoto T, Morita S, Myoshi C, Takabatake K, Kurosaki Y. Beliefs of chronically ill Japanese patients that lead to non-intentional non-adherence to medication. J Clin Pharm Ther. 2004;29:417–24.

Atkins L, Fallowfield L. Intentional and non-intentional non-adherence to medication amongst breast cancer patients. Eur J Cancer. 2006;42:2271–6.

Butow P, Palmer S, Pai A, Goodenough B, Luckett T, King M. Review of adherence-related issues in adolescents and young adults with cancer. J Clin Oncol. 2010;28(32):4800–9.

McCue DA, Lohr LK, Pick AM. Improving adherence to oral cancer therapy in clinical practice. Pharmacotherapy. 2014;34(5):481–94.

Australian Bureau of Statisics: Information paper: Outcomes of ABS reviews on remoteness consultation, Australia. In. Edited by ABS. Canberra: ABS; 2001.

Evans J, Ziebland S, Pettitt AR. Incurable, invisible and inconclusive: watchful waiting for chronic lymphocytic leukaemia and implications for doctor-patient communication. Eur J Cancer Care. 2012;21:67–77.

O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994–1004.

Burnier M. Long-term compliance with antihypertensive therapy: another facet of chronotherapeutics in hypertension. Blood Pressure Monitoring. 2000;5(Supple 1):S31–4.

Horne R, Weinman J. Patients’ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res. 1999;47(6):555–67.

Fink AK, Gurwitz J, Rakowski W, et al. Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. J Clin Oncol. 2004;22:3309–15.

Boyes AW, Girgis A, D'Este C, Zucca A. Prevalence and correlates of cancer survivors' supportive care needs 6 months after diagnosis: A population-based cross-sectional study. BMC Cancer 2012, 12(150).

Smith T, Stein KD, Mehta CC, Kaw C, Kepner JL, Buskirk T, et al. The rationale, design and implementation of the American Cancer Society's studies of cancer survivors. Cancer. 2007;109:1–12.

Thông tin
Thông tin xuất bản

Experimental Hematology & Oncology

Tập 4 Số 1

Thông tin tác giả